Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03199339 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371
A Phase 1 study, sponsored by Global Alliance for TB Drug Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT03199339 is a Phase 1 study that has completed, run by Global Alliance for TB Drug Development. The registered enrollment target is 74 participants.
The verdict
NCT03199339, a Phase 1 study, has completed, sponsored by Global Alliance for TB Drug Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects
Interventions
- DRUG Placebo
- DRUG TBA-7371
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2017-08-29 |
| Est. Completion | 2018-07-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03199339
The ClinicalTrials.gov registry entry for NCT03199339 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Global Alliance for TB Drug Development, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03199339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03199339 about?
NCT03199339 is a clinical study titled "A Phase 1 Study to Evaluate Safety, Tolerability, PK, and PK Interactions of TBA-7371". The primary objective of the study is to evaluate the safety and tolerability of single and multiple doses of TBA-7371 in healthy subjects
What is the current status of trial NCT03199339?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2017-08-29. Estimated completion is 2018-07-08.
What interventions are being tested in trial NCT03199339?
The interventions under investigation include: Placebo (DRUG), TBA-7371 (DRUG).
Who is sponsoring clinical trial NCT03199339?
This trial is sponsored by Global Alliance for TB Drug Development, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.